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Background: Mammalian target of rapamycin (mTOR) inhibitors are used in a variety of malignancies. Infections have been
reported with these drugs. We performed an up-to-date meta-analysis to further characterise the risk of infections in cancer
patients treated with these agents.
Methods: Pubmed and oncology conferences’ proceedings were searched for studies from January 1966 to June 2012. Studies
were limited to phase II and III randomised controlled trials (RCTs) of everolimus or temsirolimus reporting on cancer patients with
adequate safety profiles. Summary incidences, relative risks (RRs), and 95% confidence intervals (CIs) were calculated.
Results: A total of 3180 patients were included. The incidence of all-grade and high-grade infections due to mTOR inhibitors was
33.1% (95% CI, 24.5–43.0%) and 5.6% (95% CI, 3.8–8.3%), respectively. Compared with controls, the RR of all-grade and high-grade
infections due to mTOR inhibitors was 2.00 (95% CI, 1.76–2.28, Po0.001) and 2.60 (95% CI, 1.54–4.41, Po0.001), respectively.
Subgroup analysis found no difference in incidences or risks between everolimus and temsirolimus or between different tumour
types (renal cell carcinoma (RCC) vs non-RCC). Infections included respiratory tract (61.7%), genitourinary (29.4%), skin/soft tissue
(4.2%), and others (4.9%).
Conclusion: Treatment with mTOR inhibitors is associated with a significant increase in risk of infections. Close monitoring for any
signs of infections is warranted.
Mammalian target of rapamycin (mTOR) inhibitors are targeted
agents that have developed into an important therapeutic drug
class used in a variety of malignancies. Everolimus (Afinitor,
Novartis Pharmaceuticals, East Hanover, NJ, USA) is currently
approved by the Food and Drug Administration (FDA) for the
treatment of several malignancies including advanced renal cell
carcinoma (RCC; Motzer et al, 2008, 2010), progressive pancreatic
neuroendocrine tumours (PNET; Yao et al, 2011), subependymal
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2478 www.bjcancer.com|DOI:10.1038/bjc.2013.278giant cell astrocytomas associated with tuberous sclerosis (Krueger
et al, 2010) and most recently in combination with exemestane for
advanced hormone receptor-positive, HER-2-negative breast
cancer (Baselga et al, 2012). Temsirolimus (Torisel, Pfizer, New
York, NY, USA) is approved by the FDA for the indication of
advanced RCC (Hudes et al, 2007). This class of agents inhibits
tumour cell proliferation by first binding to an intracellular protein
(FKBP-12), which results in a protein–drug complex with mTOR,
thereby inhibiting phosphorylation of p70S6 kinase and S6
ribosomal protein in the PI3 kinase/AKT pathway (Nashan,
2002; Abraham and Gibbons, 2007). This process ultimately leads
to the downregulation of hypoxia inducible factor genes, including
vascular endothelial growth factor, necessary for cancer cell
growth, survival, and angiogenesis (Thomas et al, 2006).
Mammalian target of rapamycin inhibitors do not usually
produce the systemic toxicities that are traditionally seen with
chemotherapy such as nausea, vomiting, alopecia, and bone marrow
suppression. However, as more targeted agents are developed their
different class-specific toxicities are emerging. Trials exploring the
safety and efficacy of everolimus and temsirolimus reported some
unique side effects including rash, mucositis, infection, pneumonitis,
hyperlipidaemia, and hyperglycaemia (Hutson et al, 2008; Ravaud,
2011; Elsen et al, 2012). Specifically, infections were reported in both
everolimus and temsirolimus trials as a common side effect, as a
cause of treatment disruption, and in some cases led to fatalities
(Galanis et al, 2005; Ansell et al, 2008; Krueger et al, 2010; Motzer
et al, 2010; Sakaria et al, 2010; Tarhini et al, 2010; Budde et al,2 0 1 2 ;
Choueiri et al,2 0 1 3 ) .
The association of infection with mTOR inhibitors and its
possible clinical significance warrants further characterisation. We
sought out to assess the magnitude of this problem by looking at
the incidence and risk of infections in patients receiving mTOR
inhibitors in a large, up-to-date meta-analysis of randomised
control trials.
MATERIALS AND METHODS
Study selection. An independent review of the Pubmed databases
from January 1966 to June 2012 was conducted. Searches were
performed, limited to only human studies, with either the key
terms ‘everolimus,’ ‘Afinitor,’ ‘RAD-001’ or ‘temsirolimus,’ ‘Tor-
isel,’ ‘CCI-779.’ Citations investigating mTOR inhibitors in a non-
oncological setting were excluded. Potentially relevant abstracts
were collected and independently coded by four investigators
(MDK, GS, CJR, and TKC). The full texts of the selected abstracts
were obtained and analysed for appropriate trial design and safety
reporting. Only randomised phase II or III studies with a placebo/
control arm were used in order to properly calculate relative risk
(RR). The Jadad scale was used to assess study quality based on
study randomisation, double-blinding practice, and handling of
withdrawals (Jadad et al, 1996). When more than one publication
was drawn from the same clinical trial, the most recent or most
complete report was used. The most recent package insert for each
agent was assessed for the most current clinical information, and
the manufacturer and/or the overall investigator was contacted to
obtain clarification on infection information. The process was
duplicated using the same search terms and limitations in the
American Society of Clinical Oncology online databases of meeting
abstracts from 2000 to 2012.
Data extraction. Data extraction was conducted according to the
Preferred Reporting Items for Systemic Reviews of Meta-Analyses
statement (Moher et al, 2009). Any discrepancies between
reviewers’ classifications of publications were resolved by con-
sensus. The following information was extracted from each study:
first author’s name, year of publication, trial phase, underlying
malignancy, number of enrolled patients, treatment arms, median
age and range, median treatment duration and range, median
overall survival and 95% confidence interval (CI), number of
patients available for analysis, number of all-grade infections
attributed to study drug, and number of high-grade infections
attributed to study drug. All-grade and high-grade infections were
defined according to the National Cancer Institute Common
Toxicity Criteria version 3.0 in all trials used for the analysis.
Statistical analysis. We extracted the number of patients with all-
grade and high-grade infections and the number of patients who
were treated with mTOR inhibitors or control from the selected
clinical trials to calculate incidence. The proportion of patients
with all-grade infections and 95% CIs were derived from each trial.
RRs and 95% CIs were also calculated by comparing the incidence
of all-grade infection in patients assigned to mTOR inhibitors with
the incidence among controls in the same trial. For studies
reporting zero events in a treatment or control arm, we applied a
classic half-integer continuity correction to calculate the RR and
variance. We then repeated this for high-grade infections.
Statistical heterogeneity among trials included in the meta-
analysis was evaluated using Cochrane’s Q statistic (Cochran,
1954), and inconsistency was quantified with the I
2 statistic that
estimates the percentage of total variation across studies due to
heterogeneity rather than chance (Higgins et al, 2003). The
assumption of homogeneity was considered invalid for P-
valueso0.1. To calculate the summary incidence or RRs of all-
grade or high-grade infections, we combined trial-specific
estimates using random-effects or fixed-effects models depending
on the heterogeneity of included trials. When no substantial
heterogeneity among trials was found, the summary estimate
calculated on the basis of the fixed-effects model was reported by
using the inverse variance method. When substantial heterogeneity
among trials was observed, the summary estimate calculated on the
basis of the random-effects model was reported by using the
DerSimonian and Laird (1986) method that considers both within-
study and between-study variations. For trials with multiple
treatment groups examining varying doses of mTOR inhibitors,
we combined the treatment groups for the overall analysis.
To explore the possible reasons for the heterogeneity, we
conducted meta-regression analyses to see whether there was a
variation in risk estimates by type of drug, underlying malignancy,
type of trial, and Jadad score. In addition, we conducted sensitivity
analyses by omitting one study at a time to see the influence of
each trial on the overall effect estimate. Finally, publication bias
was evaluated through funnel plots (that is, plots of study results
against precision) and with the Begg’s and Egger’s test (Begg and
Mazumdar, 1994; Egger et al, 1997). A two-tailed P-value of o0.05
was considered statistically significant. All statistical analyses were
performed using Stata SE version 12.0 software (Stata Corporation,
College Station, TX, USA).
RESULTS
Population characteristics. Our initial search yielded a total of
366 potentially relevant abstracts in Pubmed, with 309 abstracts
searching for everolimus studies and 57 abstracts searching for
temsirolimus studies. Two hundred and thirty-five everolimus
studies were immediately excluded for not being oncological
studies. One study from the temsirolimus search was excluded for
not relating to an mTOR-inhibiting drug. Subsequently, an
additional 118 studies were excluded for one of the following
reasons: non-randomised trials, phase I trials, commentaries,
review articles, editorials, letters, or only study design reporting.
Four everolimus studies were excluded for being duplicates or
subgroup-only analyses of previously reported trial data (Motzer
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et al, 2011). The remaining eight trials, including five studies with
everolimus (Baselga et al, 2009; Motzer et al, 2010; Pavel et al,
2011; Yao et al, 2011; Baselga et al, 2012) and three studies with
temsirolimus (Hudes et al, 2007; Hess et al, 2009; Negrier et al,
2011), were selected for the meta-analysis. Of the eight selected
trials, six were phase III and two were phase II trials as shown in
the selection process outlined in Figure 1. The baseline character-
istics of each trial are presented in Table 1. There were 2233
patients from the everolimus trials and 947 patients from the
temsirolimus trials for a total of 3180 patients available for safety
analysis. The selected trials investigated patients with RCC (Hudes
et al, 2007; Motzer et al, 2010; Negrier et al, 2011), hormone
receptor-positive breast cancer (Baselga et al, 2009, 2012), PNET
(Yao et al, 2011), all types of neuroendocrine tumours (Pavel et al,
2011), and mantle cell lymphoma (Hess et al, 2009) (Table 1).
Inclusion criteria typically required that patients had good
performance status and no active baseline infection, as well as
adequate bone marrow, hepatic, pulmonary, and renal functions.
Overall incidence and types of infection. All mTOR inhibitor
treatment arms were included in the analysis to calculate the
overall incidence of infections. All-grade infections due to mTOR
inhibitors occurred in 735 patients, representing an incidence of
33.1% (95% CI, 24.5–43.0%), whereas high-grade infections
occurred in 100 patients, representing an incidence of 5.6% (95%
CI, 3.8–8.3%). When subgrouped by drug type, the incidence of all-
grade infections was 27.1% (95% CI, 16.5–41.0%) for everolimus
and 41.8% (95% CI, 26.6–58.7%) for temsirolimus. For high-grade
infection, the incidence for everolimus was 4.5% (95% CI, 2.3–
8.6%) and the incidence for temsirolimus was 7.1% (95% CI, 5.2–
9.7%). The incidence for the placebo/control arm was 15.5% (95%
CI, 10.2–22.8%) for all-grade infections and was 1.6% (95% CI,
0.8–3.1%) for high-grade infections.
All of the studies used in the meta-analysis documented
the rates of both all-grade and high-grade infections, with the
exception of one temsirolimus study that did not indicate the
incidence of high-grade infections. There were 262 (35.6%)
reported infections on mTOR inhibitors in which the type of the
infection was not otherwise specified in the studies. Of the six
studies that reported on the underlying type of infection (N¼473),
the most common were respiratory tract infections, representing
292 patients or 61.7% of all infections due to mTOR inhibitors.
Genitourinary infections (29.4%), skin/soft tissue infections (4.2%),
sepsis (1.5%), and gastrointestinal infections (0.2%) were the other
infections that were reported in the studies (Table 1). Fungal
infections, including candida (1.3%), aspergillosis (0.4%), and
others (0.2%) were reported in the studies. Viral infections,
including herpes (1.1%) and hepatitis (0.2%), and parasitic
infections (0.2%) were also reported (Table 1). Some of these
infections were severe and led to the most common cause of fatal
adverse events in the trials (Choueiri et al, 2013).
RRs of infections and subgroup analysis. All eight trials (five
everolimusþthree temsirolimus) reported the incidence of all-
grade infections and seven trials (five everolimusþtwo temsir-
olimus) reported the incidence of high-grade infections, which
were used to calculate the RRs of infections associated with mTOR
inhibitor use.
The overall RR of developing an all-grade infection for mTOR
inhibitors vs control was 2.00 (95% CI, 1.76–2.28, Po0.001). No
significant heterogeneity was found among the trials (Q¼5.02,
I
2¼0.0%, P¼0.658; Figure 2). By drug type, everolimus-treated
patients (5 trials, 1312 patients) had an increased risk of all-grade
infection, with a RR of 2.14 (95% CI, 1.81–2.53, Po0.001), and
temsirolimus-treated patients (3 trials, 612 patients) had an increased
risk of all-grade infection, with a RR of 1.81 (CI 95%, 1.48–2.22,
Po0.001). Comparing the RRs of everolimus with temsirolimus
demonstrated no significant difference (P¼0.26; Table 2).
When considering only high-grade infection events, the overall
RR for mTOR inhibitors vs control was 2.60 (CI 95%, 1.54–4.41,
Po0.001). No significant heterogeneity was found among the
studies reporting high-grade infections (Q¼7.41, I
2¼19.1%,
P¼0.284) (Figure 2). By drug type, everolimus-treated patients
(5 trials, 1,312 patients) had an increased risk of high-grade
infection, with a RR of 3.63 (95% CI, 1.66–7.94, P¼0.001).
Temsirolimus-treated patients (2 trials, 524 patients) tended to
have an increased risk of a high-grade infection, but the RR for
temsirolimus vs control (RR¼1.97; 95% CI, 0.97–4.03, P¼0.062)
did not reach a level of statistical significance because of smaller
numbers. No significant differences were observed when compar-
ing the RRs of high-grade infection between everolimus and
temsirolimus (P¼0.35; Table 2).
To determine whether the observed increases in RRs of all-grade
and high-grade infections were influenced by tumour type, we
performed a subgroup analysis of RCC, the most commonly
occurring malignancy (3 studies and 1197 total patients or 37.6%
of all patients), vs all other malignancies. The RR of all-grade
infection in patients treated with RCC was 1.84 (95% CI, 1.53–2.21;
Po0.001), whereas the RR of all-grade infection in patients with
other malignancies (five trials) was 2.18 (95% CI, 1.82–2.60;
Po0.001). No significant difference was observed in RRs of all-
grade infection between the patients with RCC or non-RCC
(P¼0.25). Similarly, the RR of high-grade infection in patients
with RCC treated with mTOR inhibitors (two trials) was 2.76 (95%
CI, 1.31–5.81; P¼0.007). For non-RCC patients (five trials), the
RR of all-grade infection was 2.46 (95% CI, 1.16–5.19; P¼0.018).
No difference was found when comparing the RRs of high-grade
infection in patients having RCC with other malignancies
(P¼0.63; Table 2).
Study quality. Randomised treatment allocation sequences were
generated in all trials used in the analysis. All five everolimus trials
were double-blinded, placebo-controlled, and of highest quality
achieving the highest Jadad score of 5. All three temsirolimus trials
were not double-blinded nor placebo-controlled, but they did all
have active treatment controls. All studies were of good
methodological quality according to the 5-point Jadad score (all
trials X3). To further assess study quality, we also compared the
RRs of all-grade and high-grade infection among phase II vs phase
III trials. There were no statistically significant differences between
Studies found in PubMed search  (n = 366)  
-Everolimus                          (n = 309)
-Temsirolimus                      (n = 57)
Studies primarily excluded (n = 354)
-Non-oncologic studies (n = 236)
-Non-randomized, phase I,
commentaries, reviews, editorials,
letters in reply (n = 118)
Studies screened  (n = 12)
-Everolimus      (n = 9)
-Temsirolimus  (n = 3)
Duplicated studies excluded (n = 4)
Trials included in the final analysis  (n = 8)
-Everolimus                           (n = 5)
-Temsirolimus                       (n = 3)
Figure 1. Selection process for randomised controlled trials included
in the meta-analysis. .
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grade P¼0.57). To assess the influence of each study on the overall
RRs of all-grade and high-grade infection, we performed a
sensitivity analysis by omitting one study at a time and found
that there were no studies that had a significant impact on the
overall RR.
Finally, we attempted to assess the possible association between
risk of infection and increased exposure to mTOR inhibitors. In
convention with other studies, we calculated the mean of the
median durations of therapy as a cut-off, which was found to be 5.8
months. When comparing the RRs of all-grade and high-grade
infections due to mTOR inhibitors amongst long-coursed trials
Relative risks of all-grade infections:
Source
No. of events/total no. of patients Relative risk
(95% CI) P-value Control mTOR inhibitor
<0.001 Baselga et al, 2012 59/238 241/482 2.02 (1.59–2.56)
0.684 1.45 (0.25–8.51) 2/132 3/137
<0.001 38/203 83/204
Baselga et al, 2009
Yao et al, 2011 2.17 (1 56–3.03)
<0.001 13/211 42/215 Pavel et al, 2011 3.17 (1.75–5.73)
<0.001 24/137 101/274 Motzer et al, 2010 2.10 (1.42–3.12)
0.003 50/200 188/416 Hudes et al, 2007 1.81 (1.39–2.35)
0.023 4/53 Hess et al, 2009 3.19 (1.17–8.67) 26/108
<0.001 Negrier et al, 2011 28/82 51/88 1.70 (1.20–2.41)
Overall 2.00 (1.76–2.28) <0.001 218/1256 735/1924
Test for heterogeneity: Q=5.02, P=0.658, I
2 =0.0 %
(Fixed-effects model)
15 1 0 0.5
Relative risks of high-grade infections:
Relative risk
(95% CI) Source
No. of events/total no. of patients
P-value
Control mTOR inhibitor
0.042 Baselga et al, 2012 4/238 24/482
0.979 Baselga et al, 2009 1/132 1/137
0.498 Yao et al, 2011 1/203 0/204
0.022 Pavel et al, 2011 1/211 11/215
0.010 1/137 Motzer et al, 2010 27/274
0.628 7/200 31/416 Hudes et al, 2007
0.065 Hess et al, 2009 2/53 6/108
Overall  <0.001 17/1174 100/1836
(Fixed-effects model)
Test for heterogeneity:  Q=7.41, P=0.284, I
2=19.1 %
1 0.1 1 5 10 50 0.02
2.96 (1.04–8.44)
0.96 (0.06–15.25)
0.33 (0.01–8.09)
10.80 (1.41–82.88)
13.50 (1.85–98.30)
2.13 (0.95–4.75)
1.47 (0.31–7.05)
2.60 (1.54–4.41)
Figure 2. Relative risks of all-grade and high-grade infections associated with mTOR inhibitors. .
Table 2. Incidences and relative risks of all-grade and high-grade infections associated with mTOR inhibitors
No. of infection/No. of
subjects Incidence
Number
of studies
mTOR
inhibitors Placebo mTOR inhibitors Placebo Relative risk (95% CI) Test for heterogeneity
All grade
Overall 8 735/1924 218/1256 33.1% (24.5–43.0) 15.5% (10.2–22.8) 2.00 (1.76–2.28);
Po0.001
Q¼5.02, P¼0.658,
I
2¼0.0%
Everolimus 5 470/1312 136/921 27.1% (16.5–41.0) 12.2% (6.8–21.1) 2.14 (1.81–2.53);
Po0.001
Q¼2.13, P¼0.711,
I
2¼0.0%
Temsirolimus 3 265/612 82/335 41.8% (26.6–58.7) 22.2% (12.4–36.5) 1.81 (1.48–2.22);
Po0.001
Q¼1.36, P¼0.506,
I
2¼0.0%
High grade
Overall 7 100/1836 17/1174 5.6% (3.8–8.3) 1.6% (0.8–3.1) 2.60 (1.54–4.41);
Po0.001
Q¼7.41, P¼0.284,
I
2¼19.1%
Everolimus 5 63/1312 8/921 4.5% (2.3–8.6) 1.0% (0.5–2.0) 3.63 (1.66–7.94);
P¼0.001
Q¼5.97, P¼0.202,
I
2¼32.9%
Temsirolimus 2 37/524 9/253 7.1% (5.2–9.7) 3.6% (1.9–6.7) 1.97 (0.97–4.03);
P¼0.062
Q¼0.17, P¼0.681,
I
2¼0.0%
Abbreviations: CI¼confidence interval; mTOR¼mammalian target of rapamycin; No.¼number.
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significant difference (all-grade P¼0.33; high-grade P¼0.80).
Publication bias. The Begg’s test and the Egger’s test were
conducted on the incidence and RR of all-grade infection, and both
showed no evidence of publication bias (for RR of all-grade
infection, Begg’s P¼0.54 and Egger’s P¼0.31). Similarly, the
Begg’s and Egger’s tests were performed on the incidence and RR
of high-grade infection, and no evidence of publication bias was
found (for RR of high-grade infection, Begg’s P¼0.55 and Egger’s
P¼0.97).
DISCUSSION
Our meta-analysis combined eight RCTs investigating mTOR
inhibitors for the treatment of cancers. To our knowledge, this is
the first large study of RCTs demonstrating a significant increase in
the risk of infection with the use of mTOR inhibitors in cancer
patients. Our analysis found that the risk of developing an infection
of any grade was two-fold higher in patients treated with mTOR
inhibitors. And, more importantly, there is a 2.6-fold increase in
the risk of high-grade infection associated with the use of
mTOR inhibitors. The observed infection risk can possibly be
explained by the potential immunosuppressant effects of mTOR
inhibitors. Everolimus and sirolimus, the principal active metabo-
lite of temsirolimus, are known to inhibit interleukin (IL)-2-, IL-7-,
and IL-15-driven proliferation of activated T cells and B cells
(Lai and Tan, 1994; Schuler et al, 1997; Shegal, 2003; Chapman and
Perry, 2004).
Although there were no statistically significant differences
between temsirolimus and everolimus when comparing their
RRs, there was a heavier contribution from everolimus to the RR
of infection, likely because of the larger number of everolimus
patients and studies used in the analysis rather than a distinctive
quality of the drug.
With an increased RR of treatment-related infections, it is clear
that proper monitoring, immediate intervention, and effective
management is crucial to achieve the maximal therapeutic benefit
of mTOR inhibitors. After reporting the incidence of infection in
everolimus-treated RCC patients, which was similar to the
incidence in our analysis (37% vs 33.1%; Motzer et al, 2010), the
RECORD-1 Study Group subsequently published recommenda-
tions for the management of infections and other adverse events
according to the grade of the event (Porta et al, 2011; Ravaud,
2011). These recommendations can be used by clinicians to
effectively manage treatment-related infections. Fungal infections
such as Candida and Aspergillosis, mycobacterial infections such as
tuberculosis, and viral infections such as hepatitis and herpes
occurred in the studies used in our analysis and were reported in
the prescribing information (Novartis, 2012; Pfizer, 2012). Patients
must be appropriately screened for viral, mycobacterial and fungal
infections in the right clinical context. Clinicians must fully treat
patients with any active infection before the initiation of mTOR
inhibitors and must monitor patients during the course of
treatment (Porta et al, 2011). Typically, patients with active or
recently active infections are excluded from clinical trials; there-
fore, the true incidence of these infections could be widely under-
reported. More trials and reporting on these patients must be done
in order to gain more insight into the management of this
subgroup of patients.
A randomised, double-blinded multicenter trial evaluated the
pharmacokinetics of temsirolimus and suggested that there may
indeed be a correlation between the cumulative exposure of
temsirolimus and certain adverse effects including infection (Boni
et al, 2005). In our meta-analysis, patients in the studies with
longer treatment durations did not have more risk to develop
infections than patients on studies with shorter treatment
durations (P40.05 for all-grade and high-grade). The findings
do not support the association of infection risk and cumulative
exposure; however, information on the time of occurrence of
infection and individual data points on treatment duration may be
needed to properly investigate the association.
Despite the size of this meta-analysis, our study has several
limitations. First, we only had access to the available data published
in the clinical trials, so there were patient variables that were not
known, such as co-morbidities, previous treatment exposure,
concomitant medications, and dose interruptions. Second, patients
in trials have adequate organ and haematological function, which
may not be the case in common oncology practice. It is conceivable
that the true incidence and risk of treatment-related adverse effects
is higher in actual practice. Third, not all of the included studies
were double-blinded, but blinding is not always possible with
parenteral administration. Although some of the included studies
were not blinded, they were all of good methodological quality.
Lastly, and despite our attempts, the reported safety data did not
disclose the specific aetiologies of all the infections that occurred.
In conclusion, the mTOR inhibitors everolimus and temsir-
olimus are associated with an increased risk of all-grade and high-
grade infections. These targeted agents are of great clinical benefit
in various malignancies and the benefits outweigh the risks in the
vast majority of cases, and thus their FDA approval. However, the
immediate detection and effective management of the potential
bacterial, viral, and fungal infections that can occur with these
agents is crucial for optimal patient outcomes.
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